Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial

J Trop Pediatr. 2010 Oct;56(5):321-4. doi: 10.1093/tropej/fmp132. Epub 2010 Jan 11.

Abstract

A randomized study was carried out to compare the efficacy and adverse reactions of daily vs. alternate day regimens of amphotericin B in children with visceral leishmaniasis (VL). Six hundred and five children of VL below 14 years of age were randomized into two groups; Group A (302), who received amphotericin B at a dose of 1 mg kg(-1) day(-1) for 15 days and Group B (303); same doses but on alternate days. All patients in both groups were cured, who had completed course of amphotericin B therapy. None had relapsed at 1 and 6 months of follow-up. Adverse reactions in both groups were non-significant. The duration of stay and cost of therapy was significantly lower in Group A children who left the hospital against medical advice, which was also significantly more in Group B. Thus, daily regimen of amphotericin B is equally effective, well tolerated, not more toxic and cost-effective than alternate day regimen, which is currently practiced.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Amphotericin B / administration & dosage*
  • Amphotericin B / economics
  • Animals
  • Antiprotozoal Agents / administration & dosage*
  • Antiprotozoal Agents / economics
  • Child
  • Child, Preschool
  • Cost-Benefit Analysis
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Infusions, Intravenous
  • Leishmania donovani / isolation & purification
  • Leishmaniasis, Visceral / diagnosis
  • Leishmaniasis, Visceral / drug therapy*
  • Male
  • Prospective Studies
  • Treatment Outcome

Substances

  • Antiprotozoal Agents
  • Amphotericin B